Proscia®, a global leader in AI-enabled pathology solutions for precision medicine, has introduced the next version of Concentriq® AP. The release includes new functionality that...
Tempus AI, Inc., a leader in artificial intelligence and precision medicine, announced that the company’s PurIST algorithmic test has received a proprietary laboratory analysis...
Tempus AI, Inc., a leader in artificial intelligence and precision medicine, announced that the Centers for Medicare & Medicaid Services (CMS) has granted Advanced...
Caris expands its extensive network of leading cancer institutions committed to improving patient outcomes through innovations in precision medicine by welcoming Mass General Cancer...
Tempus AI, Inc., a leader in artificial intelligence and precision medicine, announced it has received 510(k) clearance from the U.S. Food and Drug Administration...
Zephyr AI, a high-growth healthcare technology company committed to developing AI-Enabled Composite Biomarkers to expand the horizon of precision medicine in cancer drug development,...
xM MRD and NeXT Personal Dx tests are now available for physicians in the U.S. for early cancer recurrence detection and residual disease monitoring
Tempus,...